Stayble Therapeutics changes Certified Adviser to Svensk Kapitalmarknadsgranskning AB

Report this content

Stayble Therapeutics AB (”Stayble” or ”the Company”) hereby announces that the Company has entered into an agreement with Svensk Kapitalmarknadsgranskning AB (”SKMG”) regarding the service as Certified Adviser.

SKMG will take over as Certified Adviser on 1 April 2022. Until then, Mangold Fondkommission AB will continue to act as a Certified Adviser for the Company.

For more information

Andreas Gerward, CEO Stayble Therapeutics AB
andreas.gerward@stayble.se

+46 730 808 397

About Stayble Therapeutics AB

Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient’s life and to require minimal rehabilitation. The Company’s focus is set upon the continued clinical development and is currently conducting a clinical phase 2b. Stayble’s vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.

Mangold Fondkommission AB is the Company’s Certified Adviser and can be reached at +46 (0)8 503 015 50 or e-mail ca@mangold.se